enero 25

The Week in Healthcare: No Safe Level of Alcohol Consumption Says New Study



It was a complex week for the healthcare industry. Many of the world’s adult population received the bad news that there is no safe level of alcohol, Bayer’s recent acquisition Monsanto’s legal problems pile up and AstraZeneca’s new drug for chronic lung disease lags behind a competitor.

Mexico was warned by the UN that its health sector is vulnerable to corruption. Moreover, a recent study states that half of all diabetics do not receive appropriate treatment. President-Elect Andrés Manuel López Obrador received the National Plan for Science, Technology and Innovation 2018-2014 (STI) from industry representatives and a proposal was made to address the obesity epidemic.

Mexico Health Review spoke with CONACYT’s Director General, Enrique Cabrero, about the country’s R&D capabilities.

Now jump in last week’s highlights:


Movement Obesity Science (Movimiento Ciencia en Obesidad) gave President-Elect López Obrador a proposal to fight Mexico’s obesity epidemic.

“Human Rights and Poverty” study states that 52 percent of diagnosed diabetics do not receive appropriate treatment. The study also claims that 23.3 percent of children under five years of age have physical, motor or cognitive development problems.

The Office of the United Nations High Commissioner for Human Rights (OHCHR) warned that Mexico’s healthcare sector is extremely vulnerable to corruption.


In what will come as bad news for a large part of the world’s population, recent major study published by the Lancet reports there is no healthy level of alcohol consumption.

Shire got FDA approval for its treatment for hereditary angioedema, lanadelumab. This comes as great news for Takeda, which is buying Shire for US$62 billion.

Bayer’s troubles with Monsanto continue. The latter faces about 8,000 lawsuits from the use of glyphosate on its weed killers, a chemical that many claim has caused them cancer.

AstraZeneca’s Bevespi Aerosphere for the treatment of chronic lung disease lags behind competitor in recent clinical trial.


AstraZeneca, Bayer, Diabetes, International, Obesity

You may also like

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Get in touch

0 of 350